Migraine Disorders
📧 Sign up to get email alerts when something new happens for Migraine Disorders.
Sign up freeTop drugs studied for this disease
-
EMA approval · 2026-08-25EMA Authorised: Aquipta (atogepant) — AbbVie Deutschland GmbH & Co. KG
Aquipta (atogepant) from AbbVie has been authorised for migraine disorders in the EU.
-
EMA approval · 2026-07-02EMA Authorised: Aquipta (atogepant) — AbbVie Deutschland GmbH & Co. KG
Aquipta (atogepant) has been authorised by the EMA for migraine disorders, under AbbVie Deutschland GmbH & Co. KG.
-
EMA approval · 2026-01-27EMA Authorised: Emgality (Galcanezumab) — Eli Lilly Nederland B.V.
The European Medicines Agency authorised Emgality (galcanezumab) for migraine disorders, with Eli Lilly Nederland B.V. listed as the marketi…
-
EMA approval · 2025-06-19EMA Authorised: Aquipta (atogepant) — AbbVie Deutschland GmbH & Co. KG
The European Medicines Agency authorised Aquipta (atogepant) by AbbVie Deutschland GmbH & Co. KG for migraine disorders, marking EU regulato…
-
EMA approval · 2012-02-16EMA Refused: Sumatriptan Galpharm (sumatriptan succinate) — Galpharm Healthcare Ltd.
The EMA refused approval for Sumatriptan Galpharm (sumatriptan succinate) by Galpharm Healthcare Ltd. for migraine disorders.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.